Caterpillar-based flu shot could be on horizon

The FDA's Vaccines and Related Biological Products Advisory Committee today will determine whether Protein Sciences' flu vaccine FluBlok, which can be produced in less than two months by inserting flu genes into an insect virus and growing it in caterpillar ovary cells, warrants approval.

FluBlok can be produced in a third of the time it takes larger drugmakers, including Sanofi-Aventis, GlaxoSmithKline and Novartis, to make their chicken egg-based shots, according to a Bloomberg article. If approved, FluBlok would represent the first cell-culture derived influenza vaccine licensed in the U.S., according to FDA briefing documents posted ahead of the committee meeting.

FDA documents also revealed that the vaccine was as safe and effective as other shots. The agency made this assessment based on data from four studies of 3,231 adults.

Protein Sciences has grown to 63 employees from 40 in the last three months, and if the vaccine is approved, it may be the smallest company to receive an FDA drug approval, Daniel Adams, Protein Science's CEO, tells Bloomberg. The company may have shots ready for next flu season, he adds.

- read the Bloomberg story 
- check out the FDA briefing documents

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.